Artificial intelligencePrimary source
OpenAI acquires Orchestra Bio to accelerate drug development
OpenAI has acquired Orchestra Bio to bring AI-powered operations to life sciences research and development. The company said the deal is intended to help biopharmaceutical teams accelerate drug development and advance new treatments.
Preferred on Google
Text size
OpenAI has acquired Orchestra Bio, bringing the company into its effort to develop AI-powered operations for life sciences research and development.
OpenAI said the acquisition is intended to help biopharmaceutical teams accelerate drug development.
The company also linked the deal to advancing new treatments. The announcement did not provide financial terms, integration details or a timeline.
What we know
- OpenAI acquired Orchestra Bio for AI-powered operations in life sciences R&D.
- The deal is intended to help biopharmaceutical teams accelerate drug development.
- OpenAI linked the acquisition to advancing new treatments.
Trust: Primary source
- The story cites a primary statement. It establishes what its author said, but does not guarantee every claim is true.
- Sources: OpenAI.
COMMUNITY
Discussion
Sign in to join the discussion.
Loading comments…